Joint Program Technology and Joint Improvements. (i) Novartis, acting through patent counsel and agents of its choice, shall be responsible, at its sole cost and expense and in its sole discretion, for the preparation, filing, prosecution and maintenance of all Patent Rights claiming Joint Program Technology.
Appears in 4 contracts
Samples: Multi Target Agreement (Immunogen Inc), Multi Target Agreement (Immunogen Inc), Confidential Treatment Requested (Immunogen Inc)
